A Single-Center Clinical Trial Series on the Effectiveness and Safety of Acupuncture Robot-Assisted Human-Machine Collaborative Operation:Clinical Validation Study on Stress Urinary Incontinence

注册号:

Registration number:

ITMCTR2025001028

最近更新日期:

Date of Last Refreshed on:

2025-05-26

注册时间:

Date of Registration:

2025-05-26

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针灸机器人人机协同操作有效性与安全性的单中心临床试验系列研究:压力性尿失禁临床验证研究

Public title:

A Single-Center Clinical Trial Series on the Effectiveness and Safety of Acupuncture Robot-Assisted Human-Machine Collaborative Operation:Clinical Validation Study on Stress Urinary Incontinence

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针灸机器人人机协同操作对膝骨关节炎、压力性尿失禁、中风偏瘫的有效性与安全性的单中心临床试验研究

Scientific title:

The Efficacy and Safety of Human-AcuRobot Collaborative Operation for Knee Osteoarthritis Stress Urinary Incontinence and Stroke Hemiplegia: A pilot single-centred study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

2022YFB4703104

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

2022YFB4703104 ;

申请注册联系人:

潘兴芳

研究负责人:

潘兴芳

Applicant:

Pan Xingfang

Study leader:

Pan Xingfang

申请注册联系人电话:

Applicant telephone:

18649067519

研究负责人电话:

Study leader's telephone:

18649067519

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

panxingfang@163.com

研究负责人电子邮件:

Study leader's E-mail:

panxingfang@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市静海区团泊新城西区鄱阳湖路10号

研究负责人通讯地址:

天津市静海区团泊新城西区鄱阳湖路10号

Applicant address:

No.10 Poyanghu Road West area Tuanbo New Town Jinghai District Tianjin China

Study leader's address:

No.10 Poyanghu Road West area Tuanbo New Town Jinghai District Tianjin China

申请注册联系人邮政编码:

Applicant postcode:

301617

研究负责人邮政编码:

Study leader's postcode:

301617

申请人所在单位:

天津中医药大学

Applicant's institution:

Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024-12-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

天津市滨海新区中医医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin Binhai New District Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/12/31 0:00:00

伦理委员会联系人:

庞晓晨

Contact Name of the ethic committee:

Pang Xiaochen

伦理委员会联系地址:

天津市滨海新区北塘柳州东道292号

Contact Address of the ethic committee:

No.292 Liuzhou East Road Beitang Binhai New Area Tianjin China

伦理委员会联系人电话:

Contact phone of the ethic committee:

131 9463 8841

伦理委员会联系人邮箱:

Contact email of the ethic committee:

tgzykjk@163.com

研究实施负责(组长)单位:

天津中医药大学

Primary sponsor:

Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

天津市静海区团泊新城西区鄱阳湖路10号

Primary sponsor's address:

No.10 Poyanghu Road West area Tuanbo New Town Jinghai District Tianjin China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

天津

Country:

China

Province:

TianJin

City:

TianJin

单位(医院):

天津中医药大学

具体地址:

天津市静海区团泊新城西区鄱阳湖路10号

Institution
hospital:

Tianjin University of Traditional Chinese Medicine

Address:

No.10 Poyanghu Road West area Tuanbo New Town Jinghai District Tianjin China

经费或物资来源:

国家重点研发计划

Source(s) of funding:

National Key Research and Development Program of China

研究疾病:

压力性尿失禁

研究疾病代码:

Target disease:

Stress Urinary Incontinence

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

单臂

Single arm

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

主要目标:以压力性尿失禁为例评估智能针灸机器人系统的临床疗效 次要目标:评价智能针灸机器人对压力性尿失禁患者治疗期间的安全性、完成患者对针灸机器人期望值及满意度量表的评估。

Objectives of Study:

Primary objective: to evaluate the clinical efficacy of the intelligent acupuncture robot system in the case of stress urinary incontinence Secondary objective: to evaluate the safety of the intelligent acupuncture robot during the treatment of patients with stress urinary incontinence and to complete the assessment of patient expectations and satisfaction scales for the acupuncture robot.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 符合《第四届国际尿失禁咨询国际科学委员会的建议》及国际尿失禁学会标准化小组委员会对压力性尿失禁的诊断; 2. 病程≥1 年; 3. 用力、打喷嚏或咳嗽时不自主漏尿,应激结束时停止; 4. 可见尿道处不自主漏尿伴腹压增高,或 1 h 尿垫试验尿垫增重> 1 g; 5. 临床症状主观分度(Ingelman-Sundberg 分度)为:轻中度 SUI; 6. 性别:女性; 7. 年龄:40-75 岁。

Inclusion criteria

1. Diagnosis of stress urinary incontinence (SUI) in accordance with the recommendations of the 4th International Consultation on Incontinence ICI and the standards of the International Continence Association; 2. Course of the conditions: ≥1 year; 3. Involuntary leakage of urine during exertion sneezing or coughing stops when stress ends; 4. Observable involuntary urine leakage associated with increased abdominal pressure or a 1-hour pad test showing a weight increase > 1 g; 5. Subjective scale of clinical symptoms (Ingelman-Sundberg grading system): mild to moderate SUI ; 6. Gender: Female; 7. Age: 40–75 years.

排除标准:

1. 近 3 个月内参加其他临床试验者或进行过针灸治疗; 2. 金属及树脂类材料过敏者; 3. 妊娠或哺乳期妇女; 4. 其他类型的 UI(冲动、混合或溢出 UI 等); 5. 曾经接受过 UI 或盆腔手术; 6. 盆腔器官脱垂>2 度; 7. 残余尿量(residual urinary volume,RUV) >30 毫升; 8. 行走、爬楼梯和跑步受限; 9. 近 3 个月内接受过 SUI 的专门治疗:包括 SUI 药物,如度洛西汀,盆底肌训练(pelvic floor muscle training,PFMT)、反馈疗法、通过盆底、阴道或肛门的电刺激或磁刺激,以及经皮神经电刺激盆底),或使用影响膀胱功能的药物; 10. 有尿频、尿急等尿路感染症状; 11. 严重的心血管、脑、肝、肾或精神疾病、糖尿病、多系统萎缩、马尾损伤或脊髓病变。

Exclusion criteria:

1. Participated in other clinical trials or acupuncture treatment in the past 3 months; 2. Allergic to metals or resin materials; 3. Pregnant or breastfeeding women; 4. Other types of urinary incontinence (e.g. urge mixed overflow incontinence); 5. History of UI or pelvic surgery; 6. Pelvic organs prolapse >2nd degree; 7. Residual urinary volume (RUV) >30 mL; 8. Restrictions on walking stair climbing or running; 9. Specialized treatment for SUI in the past 3 months including SUI medications (e.g.: duloxetine) pelvic floor muscle training (PFMT) biofeedback therapy pelvic floor vaginal or anal electrical or magnetic stimulation or transcutaneous electrical nerve stimulation (TENS) of the pelvic floor or medications affecting bladder function; 10. Symptoms of urinary tract infections (e.g. frequent or intense urge to pee); 11. Severe cardiovascular cerebral liver kidney or mental illnesses diabetes multisystem atrophy cauda equina injury or spinal cord disorders.

研究实施时间:

Study execute time:

From 2025-06-01

To      2026-03-01

征募观察对象时间:

Recruiting time:

From 2025-06-08

To      2025-10-31

干预措施:

Interventions:

组别:

治疗组

样本量:

8

Group:

treatment group

Sample size:

干预措施:

针灸机器人人机协同操作

干预措施代码:

Intervention:

Human-AcuRobot Collaborative Operation

Intervention code:

样本总量 Total sample size : 8

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

天津

Country:

China

Province:

TianJin

City:

TianJin

单位(医院):

天津市滨海新区中医医院

单位级别:

三级

Institution/hospital:

Tianjin Binhai New District Hospital of Traditional Chinese Medicine

Level of the institution:

Grade III

测量指标:

Outcomes:

指标中文名:

肾功能

指标类型:

副作用指标

Outcome:

Kidney function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

1 小时尿垫试验漏尿量。

指标类型:

主要指标

Outcome:

Urine leakage amount in a 1-hour pad test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

副作用指标

Outcome:

Routine blood test

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

24 h 尿失禁发作频率

指标类型:

次要指标

Outcome:

Frequency of urinary incontinence episodes over 24 hours.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿常规

指标类型:

副作用指标

Outcome:

Routine urinalysis

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿失禁生活质量量表评分

指标类型:

次要指标

Outcome:

Incontinence Quality of Life Instrument (I-QOL) scores.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

副作用指标

Outcome:

Liver function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

针刺不良事件和反应

指标类型:

副作用指标

Outcome:

Adverse events and reactions of acupuncture

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

本研究为单臂试验。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is a single-arm experiment.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

共享时间:2026年8月20日;共享方式:邮件联系

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Shared time: August 20, 2026; Shared method: Contact by email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form (CRF)

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above